SCHEMBL1624145

SCHEMBL1624145

Cc1ccc2c(N3CCC(NC(=O)C4CC4)C3)nc(-c3c(O)cccc3F)nc2c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 4/20 0.53
MTNR1A P48039 3/20 0.37
MTNR1B P49286 3/20 0.37
ABL1 P00519 2/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MAPT P10636 1/20 0.37
USP2 O75604 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
EPHX2 P34913 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35
TSHR P16473 1/20 0.35
PTGES O14684 1/20 0.35
HRH4 Q9H3N8 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1624144 1.00 CHEK2 (0.53) CHEK2MTNR1AMTNR1BABL1ALDH1A1
Hydrochloric Acid SCHEMBL1624688 0.99 CHEK2 (0.52) CHEK2MTNR1AMTNR1BABL1ALDH1A1
Hydrochloric Acid SCHEMBL1624686 0.99 CHEK2 (0.52) CHEK2MTNR1AMTNR1BABL1ALDH1A1
SCHEMBL183939 0.92 CHEK2 (0.57) CHEK2MAPTEGLN1HRH4HRH3
SCHEMBL1623194 0.92 CHEK2 (0.57) CHEK2MAPTEGLN1HRH4HRH3
Hydrochloric Acid SCHEMBL4013463 0.92 CHEK2 (0.56) CHEK2MAPTEGLN1HRH4HRH3
Hydrochloric Acid SCHEMBL4013455 0.92 CHEK2 (0.56) CHEK2MAPTEGLN1HRH4HRH3
SCHEMBL1622587 0.88 CHEK2 (0.51) CHEK2
SCHEMBL1622592 0.88 CHEK2 (0.51) CHEK2
SCHEMBL2603698 0.88 CHEK2 (0.51) CHEK2MTNR1AMTNR1BMAPTEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-7928107-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-19 US disclosed
US-20090312342-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2009-12-17 US disclosed
EP-1784393-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-07-01 EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312342-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CHEK2 2935/4885MTNR1A 856/4885MTNR1B 812/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CHEK2 2935/4885MTNR1A 856/4885MTNR1B 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.